TIDMEDEN
RNS Number : 6218B
Eden Research plc
24 September 2018
24 September 2018
Eden Research plc ("Eden" or "the Company")
Half Yearly Report
Eden Research plc (AIM: EDEN), the AIM-listed company that
provides breakthrough biocontrol products and natural
microencapsulation technologies to the global agrochemicals, animal
health and consumer products industries, announces its interim
results for the six months ended 30 June 2018.
Financial highlights
-- Revenue for the period of GBP0.68m (H1 2017: GBP1.03m)
-- Product sales GBP0.68m (H1 2017: GBP0.43m)
-- Upfront and milestone payments of GBPnil (H1 2017: GBP0.59m)
-- Operating loss for the period of GBP0.93m (H1 2017: profit of GBP0.21m)
-- Cash and cash equivalents of GBP2.62m (H1 2017: GBP3.66m)
Business highlights
Commercial, Regulatory and IP:
-- Execution of the commercial agreements signed with Sipcam SpA in 2017
-- Expanding investment in regulatory clearances unlocking
commercial potential in new, important territories
-- United States Environmental Protection Agency ("EPA") has
commenced its scientific review of Eden's two formulated products
and their respective three active ingredients as pesticides for use
in the United States of America. These reviews are expected to
complete before the end of 2019
-- Post period end, Eden's nematicide formulation, marketed as
"Cedroz(TM)" by Eden's partner, Eastman Chemical, announced as a
finalist for "Best New Biological Product" at the prestigious AGROW
Awards
Operational highlights:
-- Lykele van der Broek, former COO of Bayer Crop Science and
former Head of the Animal Health division of Bayer Health Care,
appointed as Chairman of the Company from 1 January 2018
Lykele van der Broek, Chairman, commented:
"It is my pleasure to report to you on the good progress the
Company has made during the first six months of this year.
"The Board's focus at the start of 2018 was on increasing sales
of Mevalone (Eden's proprietary fungicide formulation), registering
existing products in new territories, evaluating new products and
evolving our Sustaine encapsulation technology in order to expand
our offering in disease and crop protection.
"Significant progress has been made in the areas of production,
formulation, regulatory, packaging and supply-chain security during
the period. These are important activities which support the growth
of the business.
"As we announced on 14 June, the United States Environmental
Protection Agency ("EPA") commenced its scientific review of two of
Eden's formulated products and their respective three active
ingredients as crop protection products for use in the United
States. We expect the outcome of these reviews to be announced
before the end of 2019.
"I am sure that the remainder of 2018 will be another
significant step-forward towards long-term success for Eden and I
would like to thank you for your continued support."
A presentation for analysts will be held at 12.30pm at
Powerscourt's offices, 1 Tudor Street, EC4Y 0AH.
Enquiries:
Eden Research plc www.edenresearch.com
Sean Smith, Chief Executive Officer Tel: 01285 359 555
Alex Abrey, Chief Financial Officer
Shore Capital and Corporate Limited www.shorecap.co.uk
Stephane Auton Tel: 020 7408 4090
Patrick Castle
Powerscourt eden@powerscourt-group.com
Nick Dibden Tel: 020 7250 1446
Jana Tsilligiannis
Eden Research plc
Chief Executive's statement for the six months ended 30 June
2018
Results
Revenue for the first half of the year was GBP0.68m compared to
GBP1.03m for the same period in 2017. This is due to one-off
payments received in 2017 which totalled GBP0.6m.
Product sales increased 58% to GBP0.68m (H1 2017: GBP0.43m).
Overheads were marginally lower than last year at GBP0.67m (H1
2017: GBP0.69m).
Loss before tax for the period was GBP0.94m (H1 2017: Profit of
GBP0.20m or a loss of GBP0.37m excluding exceptional royalties
refund).
Sales and Market Development
Eden's fungicide business, which currently consists of the sale
of our botryticide product, Mevalone, for use on table and wine
grapes as well as several other high value fruits and vegetables in
Europe and Kenya, continued to develop during the year. During the
first half of 2018, and well in advance of the peak season for the
application of Mevalone, we have seen growing interest and sales
demand from a number of our key partners.
Given the current footprint of approvals for Eden's products,
which for the moment is limited to the treatment of botrytis on
grapes in the EU's Southern Zone, sales progress has met our
expectations during the period and we expect to see an increase in
product sales volumes in the second half of 2018. The full extent
of this increase will be closely linked to the end-of-season
weather patterns and their impact on the emergence of botrytis in
the late pre-harvest period.
As authorisations in new territories are granted, we expect a
further strengthening of this business and a reduced dependency
upon regional weather patterns and the seasonality associated with
sales being limited to the northern hemisphere. Similarly, further
sales gains are expected as we expand the "label" for Mevalone to
include major new disease and crop targets.
The majority of Eden's existing partners placed repeat orders
for Mevalone during the period and we expect this to continue
through the peak of the season with some ongoing sales post season
to re-stock depleted distribution channels.
The early part of the growing season is important in
establishing the potential for botrytis to develop during the peak
risk period typically mid-to-late September when cooler and wetter
weather is prevalent. However, until this year, and since the first
launch of Mevalone in late 2016, Mevalone has been positioned
mainly as a late season botryticide, based upon its favourable risk
profile, performance, exemption from maximum residue levels and low
pre-harvest intervals. This means that unless there is an outbreak
of this disease late in the season, sales are likely to be more
modest as growers are reluctant to apply products that they
perceive as unnecessary (as would be the case in the absence of
disease). However, in conjunction with our partners, we are pleased
this year with our first efforts to position Mevalone in the early
part of the season as a treatment that is effective in reducing the
potential for the later stage development of botrytis.
Early season applications act as an insurance policy for growers
and provide for more predictable sales for Eden and our partners.
This positioning is backed by strong data which has been developed
by our partners working with leading academic experts in the field
of plant pathology. This has already translated into strong early
season sales in the territories in which this positioning was
initiated this year. We anticipate a broadening of this product
positioning in 2019 and beyond, as we are able to support early
season applications with territory specific performance data.
We have also been actively working to understand better the
needs of growers so as to refine our products and value proposition
- ultimately, with the goal of supporting our distribution partners
and increasing sales development in their countries as well as
ensuring appropriate pricing in the field. It has been pleasing to
hear feedback from growers and buying groups about their positive
experiences with Mevalone. It is also very good to hear first-hand
how biocontrol products based upon sustainable chemistry fit with
their desires for effective products that do not have the risks
associated with their use that are common with conventional
pesticides. It is important to note that growers are increasingly
concerned about the risks that pesticide residues pose to their
produce, and there is appreciation of the fact that Mevalone is
free from these risks. Produce and wine buying groups rank
pesticide residues as one of their top concerns. We view this as an
opportunity to further expand upon this message so as to drive
further sales and grow our profile with growers and value chain
influencers alike.
Investing in Regulatory Approvals
As announced on 14 June 2018, Eden has submitted its application
for the authorisation of our three active ingredients and first two
products, Mevalone and B2Y (to be marketed as Cedroz by Eastman),
in the United States. The US Environmental Protection Agency has
confirmed the initiation of its technical review. Upon approval
these authorisations will give Eden and our partners the ability to
sell Mevalone and B2Y in the US and also ease the way for the
approval of future products based upon the same active
ingredients.
We are currently pursuing registrations in a number of
additional key territories for Mevalone, and we are supporting
Eastman in seeking authorisation in nearly 30 territories for
Cedroz. Further announcements on regulatory progress will be made
as and when appropriate.
TerpeneTech
TerpeneTech is currently in the final stages of seeking
clearance to begin selling its head-lice treatment product in
European Economic Area ("EEA"), and we expect to make an
announcement on their progress in the coming weeks.
Production of the head-lice product will begin before the end of
2018 with product launch in the United Kingdom ("U.K.") in January
coinciding with the back-to-school schedule. TerpeneTech's
distribution channel in the U.K. has already been established, and
sales will commence in other countries in the EEA once arrangements
with additional distribution partners have been finalised. This is
expected to take place during 2019.
Eden plans to supply a concentrate of encapsulated active
ingredients (based upon Eden's microencapsulation technology) to
TerpeneTech who will then formulate the finished product, which
will initially be sold by its distribution partner into the
discount-retail market in the U.K.
The development, efficacy testing, and Medical Device regulatory
dossier of this head-lice treatment product has been in progress
for approximately three years. The launch of any consumer product
into a regulated market, such as the head-lice treatment products
market, is significantly more complicated, time consuming and
costly than launching products into unregulated markets. Thus,
TerpeneTech has made good progress in only three years since it was
granted a licence to use Eden's microencapsulation technology for
head-lice treatment formulations in 2015.
Commercial Partnerships
Good progress is being made through our partnerships with
Eastman Chemical, Sipcam, Sumi Agro, and Bayer Animal Health. These
partnerships provide us with many of the resources and capabilities
to achieve strong future growth. Collaborations with these partners
are on-track to deliver the results that we have anticipated for
some time, and we will update the market on the achievement of
meaningful milestones as and when appropriate.
Dividend
There was no dividend paid or proposed for the six-month period.
The Board continues to monitor its dividend policy.
Outlook
The Board is pleased with the significant commercial and
regulatory progress made over the last six months and current
trading is in line with our expectations.
Looking forward, we are well positioned for growth in line with
our strategic focus on executing on the commercial agreements with
our partners, Sipcam and Eastman, as well as gaining traction on
regulatory clearances in new territories. We also expect to see
product sales continue to increase in the second half of 2018.
I look forward to working with the Board, our team and our
partners to fully realise our ambitions this year and in the
future.
Eden Research plc
Statement of Comprehensive Income for the six months ended 30 June
2018
Six
Six months
months ended Year ended
ended 30 30 June 31 December
June 2018 2017 2017
GBP'000 GBP'000 GBP'000
unaudited unaudited audited
Revenue (note 10) 682 1,026 1,877
----------- ----------- -------------
Cost of sales (479) (312) (832)
----------- ----------- -------------
Gross profit 203 714 1,045
----------- ----------- -------------
Administrative expenses (667) (692) (1,432)
Exceptional royalties refund
(note 9) - 570 570
Licence amendment fee - - (187)
Amortisation of intangible assets (425) (387) (750)
Share based payments (note 8) (43) - (27)
----------- ----------- -------------
Total other operating expenses (1,135) (509) (1,826)
Operating (loss)/profit (932) 205 (781)
(1) - (1)
Finance costs 1 2 25
Finance income
Share of loss of equity accounted
investee, net of tax (note 7) (8) (3) (6)
----------- ----------- -------------
(Loss)/profit before tax (940) 204 (763)
Tax on (loss)/profit 4 - 124
----------- ----------- -------------
(Loss)/profit for the financial
period (936) 204 (639)
Other Comprehensive Income:
Items that will not be reclassified
subsequently to profit or loss - - -
Items that will be reclassified
subsequently to profit or loss - - -
----------- ----------- -------------
Other Comprehensive Income net
of tax - - -
Total Comprehensive Income (936) 204 (639)
Profit/(loss) per share (pence)
- basic (note 4) (0.45) 0.11 (0.33)
Profit/(loss) per share (pence)
- diluted (note 4) (0.45) 0.11 (0.34)
Eden Research plc
Consolidated Statement of Financial Position as at 30 June
2018
30 June 2018 30 June 2017 31 Dec 2017
GBP'000 GBP'000 GBP'000
unaudited unaudited audited
ASSETS
NON-CURRENT ASSETS
Intangible assets (note 6) 4,748 5,043 4,934
Investments in equity accounted
investee (note 7) 797 808 805
5,545 5,851 5,739
CURRENT ASSETS
Stock - - 207
Trade and other receivables 585 988 962
Cash and cash equivalents 2,620 3,663 3,678
3,205 4,661 4,847
TOTAL ASSETS 8,750 10,512 10,586
LIABILITIES
CURRENT LIABILITIES
Trade and other payables 1,049 1,114 2,005
TOTAL CURRENT LIABILITIES 1,049 1,114 2,005
NON-CURRENT LIABILITIES
Trade and other payables 67 67 67
TOTAL NON-CURRENT LIABILITIES 67 67 67
TOTAL LIABILITIES 1,116 1,181 2,072
EQUITY
Called up share capital 2,072 2,071 2,071
Share premium account 31,290 31,278 31,278
Merger reserve 10,210 10,210 10,210
Warrant reserve 611 615 592
Retained earnings (36,549) (34,843) (35,637)
TOTAL EQUITY attributable
to owners of the parent 7,634 9,331 8,514
TOTAL EQUITY AND LIABILITIES 8,750 10,512 10,586
Eden Research plc
Statement of Changes in Equity as at 30 June 2018
Share Share Merger Warrant Retained
capital premium reserve reserve earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Six months ended 30 June
2018
Balance at 1 January 2018
(audited) 2,071 31,278 10,210 592 (35,637) 8,514
Loss and total comprehensive
income - - - - (936) (936)
Transactions with owners
- Share issue 1 12 - - - 13
- Options granted - - - 43 - 43
- Options exercised/lapsed - - - (24) 24 -
--------- --------- --------- --------- ---------- --------
Transactions with owners 1 12 - 21 24 58
--------- --------- --------- --------- ---------- --------
Balance at 30 June 2018
(unaudited) 2,072 31,290 10,210 611 (36,549) 7,634
--------- --------- --------- --------- ---------- --------
Six months ended 30 June
2017
Balance at 1 January 2017
as restated (audited) 1,846 29,140 10,210 615 (35,047) 6,764
Profit and total comprehensive
income - - - - 204 204
Transactions with owners
- Share issue 239 2,124 - - - 2,363
- Options granted - - - - - -
- Options exercised/lapsed - - - - - -
--------- --------- --------- --------- ---------- --------
Transactions with owners 239 2,124 - - - 2,363
--------- --------- --------- --------- ---------- --------
Balance at 30 June 2017
(unaudited) 2,085 31,264 10,210 615 (34,843) 9,331
--------- --------- --------- --------- ---------- --------
Eden Research plc
Statement of cash flows for the six months ended 30 June
2018
Six months Six months
Year ended
ended ended 31
30 June 30 June December
2018 2017 2017
GBP '000 GBP '000 GBP '000
unaudited unaudited audited
Cash flows from operating activities
Cash outflow from operations
(note 5) (836) (16) 223
Tax credit received 4 - 8
Finance costs (1) - (1)
----------- ----------- -----------
Net cash used in operating
activities (833) (16) 230
Cash flows from investing activities
Capitalisation of development
expenditure (239) (218) (324)
Capitalisation of patents - - (148)
Foreign exchange gains - - 23
Finance income 1 2 3
----------- ----------- -----------
Net cash used in investing
activities (238) (216) (447)
----------- ----------- -----------
Cash flows from financing activities
Share issue costs - (35) (35)
Issue of equity shares 13 2,398 2,398
----------- ----------- -----------
Net cash from financing activities 13 2,363 2,538
----------- ----------- -----------
(Decrease)/increase in cash
and cash equivalents (1,058) 2,131 2,146
Cash and cash equivalents at
beginning of period 3,678 1,532 1,532
----------- ----------- -----------
Cash and cash equivalents at
end of period 2,620 3,663 3,678
=========== =========== ===========
Cash and cash equivalents comprise bank account balances.
Notes to the Interim Results
1. The information in these financial statements does not
constitute statutory accounts as defined in section 434 of the
Companies Act 2006 and is un-audited. These financial statements
have been prepared in accordance with the AIM rules, and IAS 34 has
not been adopted. A copy of the Company's statutory accounts for
the period ended 31 December 2017, prepared under International
Financial Reporting Standards as adopted by the European Union, has
been delivered to the Registrar of Companies and are available on
the Company's website. The auditors' report on those accounts was
unqualified and did not contain statements under section 498(2) or
section 498(3) of the Companies Act 2006.
2. Nature of operations and general information
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer product industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
3. Accounting Policies
Basis of Preparation
These interim condensed consolidated financial statements are
for the six months ended 30 June 2018. They have been prepared
following the recognition and measurement principles of IFRS. They
do not include all of the information required for full annual
financial statements and should be read in conjunction with the
financial statements of the company for the year ended 31 December
2017.
These financial statements have been prepared on the going
concern basis and under the historical cost convention.
Going Concern
The financial statements have been prepared on a going concern
basis which contemplates the realisation of assets and the
settlement of liabilities in the ordinary course of business.
The Company has reported a loss for the period after taxation of
GBP936,000 (2017: profit of GBP204,000). Net current assets at that
date amounted to GBP2,156,000 (2017: GBP3,547,000).
The directors have prepared budgets and projected cash flow
forecasts, based in part on forecasts provided by Eden's commercial
partners, for a period of two years from 31 December 2017 and they
consider that the Company will be able to operate with the cash
resources that are available to it for this period. The ability of
the Company to continue as a going concern is ultimately dependent
upon the amounts and timing of cash flows from the exploitation of
the Company's intellectual property and the availability of
additional funding to meet the short term needs of the business
until the commercialisation of the Company's portfolio is
reached.
The forecasts adopted only include revenue derived from existing
contracts and, while there is a risk these payments might be
delayed if milestones are not reached, there is also potential
upside from on-going discussions and negotiations with other
parties, as well as other "blue sky" opportunities.
In addition, the Company has relatively low fixed running costs
and has a demonstrable ability to delay certain other costs, such
as the forecast Research and Development expenditure, in the event
of unforeseen cash constraints.
The directors have also considered a scenario whereby the
Company receives no revenue from the date of this Report. On this
basis, the directors believe that the Company has sufficient cash
to cover a period of at least 12 months from the date of this
Report.
The directors have been and will continue to closely monitor
performance against cash flow projections that have been prepared
for the period to 31 December 2019, and beyond, and are confident
that the Company will be able to rely on the necessary cash
resources at least at the levels referred to above.
On this basis, the directors consider it appropriate to prepare
the financial statements on the going concern basis. The financial
statements do not include any adjustments that would result from a
failure by the Company to meet these forecasts.
These condensed consolidated interim financial statements have
been prepared in accordance with the accounting policies adopted in
the last annual financial statements for the year to 31 December
2017, except for the application of the following standards at 1
January 2018:
-- IFRS 15 "Revenue from Contracts with Customers"
IFRS 9 "Financial Instruments"
-- Annual Improvements 2014-16 (Annual Improvements)
The accounting policies have been applied consistently for the
purposes of preparation of these condensed interim financial
statements.
Copies of the interim statement are available from the Company
at its registered office, 6 Priory Court, Priory Court Business
Park, Poulton, Cirencester, Gloucestershire, GL7 5JB, as well as on
the Company's website.
4. Profit/(loss) per share
Six months Six months Year ended
ended ended 31 December
30 June 30 June 2017 2017
2018 Pence unaudited Pence
Pence unaudited audited
(Loss)/profit per ordinary share
(pence) - basic (0.45) 0.11 (0.33)
(Loss)/profit per ordinary share
(pence) - diluted (0.45) 0.10 (0.34)
================= ================= =============
(Loss)/profit per share - basic has been calculated on the net
basis on the loss after tax of GBP936,000 (30 June 2017: profit
GBP204,000, 31 December 2017: GBP639,000) using the weighted
average number of ordinary shares in issue of 207,103,702 (30 June
2017: 184,654,119, 31 December 2017: 195,705,733).
(Loss)/profit per share - diluted has been calculated on the net
basis on the loss after tax of GBP936,000 (30 June 2017: profit
GBP204,000, 31 December 2017: GBP639,000) using the weighted
average number of ordinary shares in issue of 207,365,489 (30 June
2017: 184,140,041, 31 December 2017: 190,686,632).
5. Reconciliation of loss before income tax to cash used by operations
Six months Six months Year ended
ended ended 31 December
30 June 30 June 2017
2018 2017 GBP GBP '000
GBP '000 '000 unaudited audited
unaudited
(Loss)/profit after tax (936) 204 (639)
Share of associate's losses 8 3 6
Amortisation charges 425 387 750
Share based payment charge 43 - 27
Finance costs 1 - 1
Finance income (1) (2) (25)
Tax credit (4) - (124)
----------- ---------------- -------------
(464) 592 (3)
(Decrease)/increase in trade
and other receivables 377 (757) (606)
Increase/(decrease) in trade
and other payables (956) 149 1,039
Decrease/(increase) in stock 207 - (207)
----------- ---------------- -------------
Cash used by operations (836) (16) 223
=========== ================ =============
6. Intangible assets
Intellectual Licences Development Total
property and trademarks Costs
GBP '000 GBP '000 GBP '000 GBP '000
COST
At 1 January 2017 8,740 447 3,455 12,642
Additions - 115 103 218
------------- ---------------- ------------ ---------
At 30 June 2017 8,740 562 3,558 12,860
Additions 148 (115) 221 254
------------- ---------------- ------------ ---------
At 31 December 2017 8,888 447 3,779 13,114
Additions - - 240 240
------------- ---------------- ------------ ---------
At 30 June 2018 8,888 447 4,019 13,354
============= ================ ============ =========
AMORTISATION
At 1 January 2017 5,571 384 1,475 7,430
Charge for the period 220 8 159 387
------------- ---------------- ------------ ---------
At 30 June 2017 5,791 392 1,634 7,817
Charge for the period 220 13 131 364
------------- ---------------- ------------ ---------
At 31 December 2017 6,011 405 1,765 8,181
Charge for the period 240 13 172 425
------------- ---------------- ------------ ---------
At 30 June 2018 6,251 418 1,937 8,606
============= ================ ============ =========
CARRYING AMOUNT
At 30 June 2018 2,637 29 2,082 4,748
============= ================ ============ =========
At 31 December 2017 2,877 43 2,014 4,934
============= ================ ============ =========
At 30 June 2017 2,949 170 1,924 5,043
============= ================ ============ =========
7. Investment in equity accounted investee
Six months Six months Year ended
ended ended
30 June 2018 30 June 2017 31 December
2017
GBP '000 GBP '000 GBP '000
unaudited unaudited audited
Percentage ownership interest
and proportion of voting rights 29.90% 29.90% 29.90%
GBP GBP GBP
Non-current assets 592 608 584
Current assets 140 190 134
Non-current liabilities (98) (73) (44)
Current liabilities (13) (93) (28)
-------------
Net assets (100%) 621 632 645
Company's share of net assets 186 189 193
Separable intangible assets 199 206 199
Goodwill 413 413 413
-------------
Carrying amount of interest
in associate 797 808 805
Revenue 116 148 225
Profit/(loss) from continuing
operations (5) 13 28
Post tax profit from discontinued - - -
operations
100% of total post-tax profits (5) 13 28
29.9% of total post-tax profits (1) 4 8
Amortisation of separable intangible
assets (7) (7) (15)
------------- ------------- ------------
Company's share of profit/(loss) (8) (3) (6)
Other comprehensive income - - -
100% - - -
29.90% - - -
Company's share of other comprehensive - - -
income
Total comprehensive income
(100%) (5) 13 28
Company's share of total comprehensive
income (8) (3) (6)
Dividends received by the - - -
Company
8. Share based payments
Share Options
Unapproved option scheme
Eden Research plc operates an unapproved option scheme for
executive directors, senior management and certain employees.
Six months ended 30 June Six months ended 30
2018 June 2017
Weighted Weighted
average average
exercise exercise
price (pence) Number price (pence) Number
Outstanding at the
beginning
of the period 11 5,025,000 11 5,025,000
Granted during the
period - - - -
Exercised during the
period - (125,000) - -
Lapsed during the period - (500,000) - -
11 4,400,000 11 5,025,000
The exercise price of options outstanding at the end of the
period ranged between 8p and 16p (30 June 2017: 8p and 18p) and
their weighted average contractual life was 1 year (30 June 2017:
1.4 years). None of the options have vesting conditions.
The weighted average share price (at the date of exercise) of
options that lapsed during the period was nil p (30 June 2017:
13p).
The share-based payment charge for the period was GBP42,686 (30
June 2017: GBPnil).
Long-Term Incentive Plan ("LTIP")
Eden Research Plc operates an unapproved option scheme for
executive directors, senior management and certain employees under
a LTIP which it adopted in 2017.
During the year ended 31 December 2017, the following options
were granted under the LTIP:
Number of Fair value Total fair
Description Date of grant awards granted per award GBP value GBP
2015 awards 28/09/2017 1,908,680 0.0601 114,712
2016 awards 28/09/2017 2,108,000 0.0461 97,179
________ ______
4,016,680 211,891
The share-based payment charge for the year ended 31 December
2017 and subsequent years is set out as follows:
Financial year ended Share based
31 December payment charge GBP
2017 27,210
2018 85,372 (H1, 2018: GBP42,686)
2019 75,108
2020 24,201
______
211,891
The following information is relevant in the determination of
the fair value of options granted during the year under the
unapproved options scheme under the LTIP operated by Eden Research
Plc.
2015 Award 2016 Award
Grant date 28/09/17 28/09/17
Number of awards 1,908,680 2,108,000
Share price GBP0.125 GBP0.125
Exercise price GBPnil GBPnil
Expected dividend yield -% -%
Expected volatility 73.20% 73.20%
Risk free rate 0.80% 0.80%
Vesting period 2 years 3 years
Expected Life (from date of grant) 10 years 10 years
For those options and warrants which were not granted under the
Company's LTIP, fair value is measured using the Black-Scholes
model. The expected life used in the model has been adjusted, based
on management's best estimate, for the effects of
non-transferability, exercise restrictions and behavioural
conditions.
For those options which were granted under the Company's LTIP,
Monte Carlo techniques were used to simulate future share price
movements of the Company to assess the likelihood of the
performance criteria being met and the fair value of the awards
upon vesting. The modelling calculates many scenarios in order to
estimate the overall fair value based on the average value where
awards vest.
Warrants
Six months ended 30 June Six months ended 30
2018 June 2017
Weighted Weighted
average average
exercise exercise
price (pence) Number price (pence) Number
Outstanding at the
beginning
of the period 14 3,350,000 14 5,497,867
Granted during the
period - - - -
Lapsed during the period - - - -
14 3,350,000 14 5,497,867
The exercise price of warrants outstanding at the end of the
period ranged between 11p and 30p (30 June 2017: 11p and 30p) and
their weighted average contractual life was 1.4 years (30 June
2017: 1.7 years).
9. Exceptional royalties refund
In the year ended 31 December 2017, an accrual had been made of
GBP570,000, being minimum royalties due to University of
Massachusetts Medical School ("UMMS") under the licence agreement
Eden signed with UMMS in 2011. Eden successfully re-negotiated some
of the terms of the licence with UMMS and, as such, the full amount
accrued was credited to the Income Statement in the year ended 31
December 2017.
10. Segmental reporting
IFRS 8 requires operating segments to be reported in a manner
consistent with the internal reporting provided to the chief
operating decision-maker. The chief operating decision-maker, who
is responsible for the resource allocation and assessing
performance of the operating segments has been identified as the
Executive Directors as they are primarily responsible for the
allocation of the resources to segments and the assessment of
performance of the segments.
The Executive Directors monitor and then assess the performance
of segments based on product type and geographical area using a
measure of adjusted EBITDA. This is the result of the segment after
excluding the share based payment charges, other operating income
and the amortisation of intangibles. These items, together with
interest income and expense are not allocated to a specific
segment.
The segmental information for the six months ended 30 June 2018
is as follows:
Licensing Milestone Evaluation Royalties Grant Product Un-allocated Total
Fees Payments Fees Funding Sales
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
GBP '000 GBP '000 GBP '000 GBP GBP GBP '000 GBP '000 GBP '000
'000 '000
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Human - - - - - - - -
health
and biocides
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Animal - - - - - - - -
health
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Agrochemicals - - - - - 682 - 682
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
TOTAL - - - - - 682 - 682
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Adjusted
EBITDA - - - - - - (464) (464)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Amortisation - - - - - - (425) (425)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Depreciation - - - - - - - -
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Share
Based
Payments - - - - - - (43) (43)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Net Finance - - - - - - - -
Costs
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Income
Tax - - - - - - 4 4
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Share
of Associate's
loss - - - - - - (8) (8)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Loss for
the Period - - - - - - (936) (936)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Total
Assets - - - - - - 8,750 8,750
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Total
assets
includes:
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Additions
to Non-Current
Assets - - - - - - 240 240
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
Total
Liabilities - - - - - - (1,116) (1,116)
----------- ----------- ------------ ----------- ---------- --------- ------------- ---------
The segmental information for the six months ended 30 June 2017
is as follows:
Licensing Milestone Evaluation Royalties Grant Product Un-allocated Total
Fees Payments Fees Funding Sales
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
GBP '000 GBP '000 GBP '000 GBP GBP GBP '000 GBP '000 GBP '000
'000 '000
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Human - - - - - - - -
health
and biocides
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Animal - - - - - - - -
health
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Agrochemicals - 592 - - - 434 - 1,026
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
TOTAL - 592 - - - 434 - 1,026
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Adjusted
EBITDA - - - - - - 592 592
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Amortisation - - - - - - (387) (387)
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Depreciation - - - - - - - -
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Share - - - - - - - -
Based
Payments
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Net Finance
Income - - - - - - 2 2
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Income - - - - - - - -
Tax
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Share
of Associate's
loss - - - - - - (3) (3)
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Profit
for the
Period - - - - - - 204 204
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
Assets - - - - - - 10,512 10,512
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
assets
includes:
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Additions
to Non-Current
Assets - - - - - - 218 218
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
Liabilities - - - - - - (1,181) (1,181)
----------- ---------- ----------- ---------- --------- --------- ------------- ---------
The segmental information for the year ended 31 December 2017 is
as follows:
Licensing Milestone Evaluation Royalties Grant Product Un-allocated Total
Fees Payments Fees Funding Sales
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
GBP '000 GBP '000 GBP '000 GBP GBP GBP '000 GBP '000 GBP '000
'000 '000
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Human
health
and biocides 15 - - 13 - - - 28
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Animal - - - - - - - -
health
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Agrochemicals - 968 - 116 - 765 - 1,849
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
TOTAL 15 968 - 129 - 765 - 1,877
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Adjusted
EBITDA - - - - - - (3) (3)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Amortisation - - - - - - (750) (750)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Depreciation - - - - - - - -
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Share
Based
Payments - - - - - - (27) (27)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Net Finance
Income - - - - - - 24 24
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Income
Tax - - - - - - 124 124
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Share
of Associate's
loss - - - - - - (6) (6)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Loss for
the Year - - - - - - (639) (639)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
Assets - - - - - - 10,586 10,586
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
assets
includes:
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Additions
to Non-Current
Assets - - - - - - 472 472
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Total
Liabilities - - - - - - (2,072) (2,072)
---------- ---------- ----------- ---------- --------- --------- ------------- ---------
Geographical Reporting
Six months Six months Year ended
ended ended 31 December
30 June 30 June 2017
2018 2017
GBP '000 GBP '000 GBP '000
UK - - 28
Europe 682 1,026 1,849
----------- ----------- -------------
682 1,026 1,877
=========== =========== =============
The revenue derived from Milestone Payments and Licensing Fees
relates to agreements which cover a number of countries both in the
EU and throughout the rest of the world.
All of the non-current assets are in the UK.
Other notes:
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer products industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP13m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, 3AEY, were approved as new ingredients for use
in plant protection products. This represented a major milestone in
the commercialisation of Eden's technology and is a significant
accomplishment for any company. To illustrate this point, one
should note that in all of 2013, Eden's approvals represented 3 of
only 10 new active ingredients approved by the EC.
3AEY has been authorised for sale in Kenya, Malta, Greece,
Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR SEAFUFFASESU
(END) Dow Jones Newswires
September 24, 2018 02:00 ET (06:00 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024